UK markets open in 1 hour 1 minute

Pfizer Inc. (0Q1N.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
50.83+0.25 (+0.49%)
At close: 07:12PM BST
Full screen
Previous close50.58
Open50.82
BidN/A x N/A
AskN/A x N/A
Day's range50.26 - 50.82
52-week range33.27 - 54.90
Volume247,152
Avg. volume236,987
Market capN/A
Beta (5Y monthly)0.55
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Business Wire

    Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV

    NEW YORK, September 22, 2023--Pfizer Inc. (NYSE: PFE) shared today it has broadened its portfolio of respiratory vaccines recommended by the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) following a favorable vote for ABRYSVO™ [Respiratory Syncytial Virus Vaccine], the company’s bivalent RSV prefusion F (RSVpreF) vaccine, as a maternal immunization. This is the first-ever fall in which eligible individuals can receive Pfizer vaccines

  • Business Wire

    Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

    NEW YORK, September 19, 2023--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023 at 3:30 p.m. EDT.

  • Business Wire

    European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata

    NEW YORK, September 19, 2023--Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for LITFULO™ (ritlecitinib) to treat adults and adolescents 12 years of age and older with severe alopecia areata. LITFULO, a once-daily oral capsule, is the first medicine authorized by the EC to treat individuals as young as 12 years of age with severe alopecia areata. LITFULO is also the first and only treatment to selectively inhibit Janus kinase 3 (JAK3